IntrinsicIntrinsic
← All summaries

BRUKER CORP

BRKR
Financials & Chart →

Business Summary

Bruker Corporation (BRKR) is a developer, manufacturer, and distributor of high-performance scientific instruments and analytical and diagnostic solutions, enabling customers to explore life and materials at microscopic, molecular, and cellular levels. The company's products are utilized across diverse sectors including life and materials science research, biopharmaceuticals, applied markets, microbiology, in-vitro diagnostics, and nanotechnology. Bruker's technology platforms encompass magnetic resonance, mass spectrometry, gas and liquid chromatography, X-ray, microscopy, metrology, and molecular spectroscopy. The company's revenue generation is primarily transactional from product sales, complemented by recurring service and other revenue. Its customer base is broad and diversified, with no single customer accounting for more than 10% of revenue in the last three fiscal years through December 31, 2025, or more than 10% of accounts receivable as of December 31, 2025, and 2024 .

Bruker operates through four reportable segments: BSI BioSpin, BSI CALID, BSI NANO, and Bruker Energy & Supercon Technologies (BEST). The BSI BioSpin segment focuses on magnetic resonance technology, including NMR and EPR products, preclinical imaging solutions (MRI, PET, SPECT, CT, MPI, BLI, FLI), biopharma and applied market solutions, services and lifecycle support, integrated data solutions, and lab automation. Its primary customers are academic and government research facilities, pharmaceutical and biotechnology companies, and industrial users . The BSI CALID segment designs, manufactures, and distributes life science mass spectrometry, applied mass spectrometry, microbiology and infection diagnostics solutions (MALDI-TOF, ESI-TOF, MRMS, ITMS, IMS, GC-MS, DART-MS, LC-MS, PCR), Bruker Optics (infrared and Raman molecular spectroscopy), and CBRNE detection products. Customers include pharmaceutical, biotechnology, and diagnostics companies, academic institutions, and government agencies . The BSI NANO segment provides advanced X-ray instruments (XRF, µXRF, TXRF, XRD, µCT, OES, STEM, EDS, EBSD), Bruker Nano Surfaces and Metrology (AFM, SOM, TMT, NanoIR, Alicona), Bruker Spatial Biology (CosMx Spatial Molecular Imager, GeoMx Digital Spatial Profiler, nCounter, Cellscape, PaintScape), and the Consolidated Fluorescence Microscopy and Cellular Analysis Business Units. Its customers span academic institutions, nanotechnology, semiconductor, raw material, industrial, biotechnology, and pharmaceutical companies . The BEST segment develops and manufactures superconducting materials (LTS, HTS) and non-superconducting high technology tools (synchrotron and beamline instrumentation, Cuponal™) for applications in medical, clinical, pharmaceutical, high-energy physics, renewable energy, and environmental research .

For the fiscal year ended December 31, 2025, Bruker reported total revenue of $3,436.5 million , representing a year-over-year growth rate of 2.1% . Product revenue was $2,766.4 million , and service and other revenue was $670.1 million . Gross profit for the period was $1,577.7 million , resulting in a gross profit margin of 45.9% . Operating income was $68.2 million , with an operating income margin of 2.0% . The company reported a consolidated net loss of $8.3 million , and a net loss attributable to Bruker Corporation common shareholders of $22.5 million . Diluted EPS was $(0.15) . Net cash provided by operating activities was $134.1 million , and free cash flow was $43.3 million . As of December 31, 2025, cash and cash equivalents stood at $298.8 million , total long-term debt was $1,852.5 million , and the current portion of long-term debt and finance lease obligations was $16.6 million .

Comparing fiscal year 2025 to 2024, total revenue increased by $70.1 million , or 2.1% . Product revenue saw a modest increase of $7.2 million , or 0.3% , while service and other revenue grew by $62.9 million , or 10.4% . Gross profit decreased by $71.8 million , a 4.4% decline , leading to a contraction in gross profit margin from 49.0% in 2024 to 45.9% in 2025 . Operating income experienced a significant decrease of $184.9 million , or 73.1% , with the operating margin falling from 7.5% in 2024 to 2.0% in 2025 . This decline was primarily attributed to unfavorable revenue mix, increased restructuring costs and impairment charges, the impact of U.S. tariffs, and foreign exchange headwinds from a declining U.S. Dollar .

Segment-wise, BSI CALID revenue increased by $116.7 million , or 10.7% , driven by increased volumes from the Optics and Microbiology & Infection Diagnostics divisions, including activity in Security Detection products, the MALDI Biotyper business, and the ELITechGroup molecular diagnostics business acquired in Q2 2024 . BSI NANO revenue declined by $14.0 million , or 1.3% , due to weaker demand in academic, government research, and industrial markets for analytical instruments and the Nano Surfaces and Metrology division, partially offset by NanoString, acquired in Q2 2024 . BSI BioSpin revenue decreased by $26.9 million , or 3.0% , primarily due to fewer GHz-class NMR system sales (two in 2025 versus four in 2024) and weaker demand in the biopharma market and NMR instruments, partially offset by stronger demand in lab automation products . BEST revenue decreased by $12.1 million , or 4.3% , mainly due to softness in the clinical MRI market and a strong prior-year comparison for the Research Instruments business .

Significant operational developments during 2025 included the launch of the MOVE-T solution for dairy markets and the VERTEX NEO R FTIR research spectrometer within BSI CALID . Several new technologies and workflows were introduced in Mass Spectrometry, such as timsOmni, timsMetabo, timsUltra Athena Ion Processor (AIP), and proteoElute, advancing proteomics and multiomics . The company completed the acquisition of Recipe Chemicals + Instruments GmbH, AST Revolution, LLC, and certain other acquisitions and minority investments . Recipe enhances capabilities in small molecule clinical diagnostic assays for liquid chromatography triple-quadrupole mass spectrometers , while AST Revolution, LLC, an in vitro diagnostics company, supports rapid antimicrobial susceptibility testing . Within BSI BioSpin, two additional 1.2 GHz NMR systems were successfully installed, advancing ultra-high field access . The company also completed certain minority investments in BSI BioSpin and BSI NANO to expand technological capabilities, enter new markets, and enhance product portfolios . A goodwill impairment charge of $96.5 million was recorded in 2025, primarily affecting the Bruker Spatial Biology (BSB) reporting unit within BSI NANO and the Automation (AUT) reporting unit within BSI BioSpin .

Business Outlook

Bruker anticipates that its existing cash and cash equivalents and credit facilities will be sufficient to support its operating and investing needs, and other liquidity needs for at least the next twelve months and the foreseeable future under the currently anticipated business conditions and macroeconomic environment . The company expects capital expenditures in 2026 to be consistent with the level of investing in 2025 . Interest expense is projected to decrease in 2026 primarily due to lower debt levels following repayments made during 2025 .

The company is focused on integrating the businesses and assets acquired in 2024 and prior years, indicating a period of consolidation rather than aggressive new acquisition activity . Bruker announced a cost savings initiative in August 2025, targeting annualized cost reductions of approximately $100 million to $120 million by the end of 2026 . These planned reductions are expected across all parts of the business, including supply chain, manufacturing, commercial operations, administrative functions, and research and development, with the intention to improve operating income and operating margins on a company-wide basis .

Bruker's research and development strategy involves continuous innovation to enhance system performance, improve product reliability, develop revolutionary new products and solutions, and maintain technical competencies in core technology platforms . The company commits substantial resources to internal and collaborative R&D projects, historically exceeding the industry average . Access to R&D capabilities is also gained through acquisitions of intellectual property, technology, and expertise . Specific R&D efforts include advancements in ultra-high-field NMR and MRI, benchtop Fourier NMR, innovative timsTOF mass spectrometers, new sample preparation and automation workflows for proteomics, and EBSD detectors for electron microscopes .

The company is monitoring the implementation of the OECD Pillar Two global minimum tax regime by various countries in which it operates . While some countries have adopted legislation, and others are in process, the U.S. has withdrawn support for Pillar Two, and a side-by-side agreement was reached on January 5, 2026, to exempt U.S. multi-nationals from certain Pillar Two taxes by recognizing the U.S. tax system as a compatible domestic minimum tax regime . Bruker will continue to monitor these developments, which could increase tax complexity and potentially affect its income tax provision .

Risk Factors

Bruker faces numerous risks, including supply chain disruptions leading to increased costs and manufacturing inefficiencies, adverse global economic conditions, and geopolitical tensions in regions like Ukraine, the Middle East, and China, which could negatively impact revenue, operating results, and financial condition . New U.S. and reciprocal tariffs, subject to change and uncertainty, have already adversely affected gross margins, operating margins, and profitability in 2025 due to increased cost of goods sold . Delays in Chinese government stimulus spending and reductions or delays in U.S. academic and government funding (NIH, NSF, DOE) for high-end research instrumentation have materially impacted sales growth in China and the U.S., respectively, and are expected to continue for the foreseeable future . International sales, representing approximately 74% of total consolidated revenue in 2025 , expose the company to foreign currency fluctuations, regulatory changes, political and economic instability, and compliance with various international laws, including GDPR, which could disrupt data transfers and incur significant fines . Goodwill, intangible assets, and other long-lived assets are subject to impairment, as evidenced by the $96.5 million goodwill impairment charge in 2025 , and further charges may be incurred if fair values decline . The markets for Bruker's products are characterized by rapid technological change, posing a risk of product obsolescence if the company fails to continually innovate . Substantial competition from established companies, some with greater resources, could lead to pricing pressure and market share loss . Disruptions at any of the company's manufacturing facilities, many of which are single-location, could severely affect production and customer relationships . Cybersecurity risks, including attacks and data breaches, could impact operations, financial results, and reputation . The company's debt, totaling approximately $1.9 billion as of December 31, 2025 , and largely denominated in foreign currency, is subject to interest rate and foreign currency fluctuations, potentially affecting cash flow and restricting investment opportunities . Changes in effective income tax rates due to jurisdictional mix, tax law changes (including the OBBBA and Pillar Two), and international tax risks could adversely affect earnings and cash flows . The highly concentrated ownership of shares by Laukien family members (approximately 32% as of December 31, 2025) could cause stock price volatility and influence corporate decisions . Dependence on a limited number of suppliers and contract manufacturers for critical components, such as ceramics, detectors, X-ray tubes, and niobium-titanium for superconductors, creates vulnerability to supply shortages and price increases, which could adversely affect gross profit .

Management Priorities

Management's message to shareholders emphasizes a commitment to ongoing innovation as a core strategy to drive scientific research, develop new markets, enhance product and service offerings, and maintain leadership and relevance in its industries . The company is focused on enhancing customer relationships and driving innovation through key initiatives, including expanding into high-potential markets, leveraging core strengths, and driving recurring revenue through aftermarket and connected services . Management explicitly stated that existing cash and cash equivalents and credit facilities are anticipated to be sufficient to support operating and investing needs, and other liquidity needs for at least the next twelve months and the foreseeable future under currently anticipated business conditions and macroeconomic environment . Capital expenditures in 2026 are expected to be consistent with the level of investing in 2025 , and interest expense is projected to decrease in 2026 primarily due to lower debt levels following repayments made during 2025 . A significant strategic priority is the cost savings initiative announced in August 2025, aimed at reducing annualized costs by approximately $100 million to $120 million by the end of 2026 , with reductions planned across all business functions to improve operating income and operating margins . The Board of Directors declared a quarterly dividend of $0.05 per share payable in April 2026 .

View Source Annual Report on SEC.gov ↗

References

  1. [1] Item 1, Business
  2. [2] Item 1, Business
  3. [3] Item 1, Business
  4. [4] Item 1, Business
  5. [5] Item 1, Business
  6. [6] Item 1, Business
  7. [7] Item 1, Business
  8. [8] Item 1, Business
  9. [9] Item 1, Business
  10. [10] Item 1, Business Segments
  11. [11] Item 1, Business Segments
  12. [12] Item 1, Business Segments
  13. [13] Item 1, Business Segments
  14. [14] Item 7, MD&A — Consolidated Results
  15. [15] Item 7, MD&A — Consolidated Results
  16. [16] Item 7, MD&A — Consolidated Results
  17. [17] Item 7, MD&A — Consolidated Results
  18. [18] Item 7, MD&A — Consolidated Results
  19. [19] Item 7, MD&A — Consolidated Results
  20. [20] Item 7, MD&A — Consolidated Results
  21. [21] Item 7, MD&A — Consolidated Results
  22. [22] Item 7, MD&A — Consolidated Results
  23. [23] Item 7, MD&A — Consolidated Results
  24. [24] Item 7, MD&A — Consolidated Results
  25. [25] Item 7, MD&A — Consolidated Results
  26. [26] Item 7, MD&A — Consolidated Results
  27. [27] Item 8, Consolidated Balance Sheets
  28. [28] Item 8, Consolidated Balance Sheets
  29. [29] Item 8, Consolidated Balance Sheets
  30. [30] Item 7, MD&A — Consolidated Results
  31. [31] Item 7, MD&A — Consolidated Results
  32. [32] Item 7, MD&A — Consolidated Results
  33. [33] Item 7, MD&A — Consolidated Results
  34. [34] Item 7, MD&A — Consolidated Results
  35. [35] Item 7, MD&A — Consolidated Results
  36. [36] Item 7, MD&A — Consolidated Results
  37. [37] Item 7, MD&A — Consolidated Results
  38. [38] Item 7, MD&A — Consolidated Results
  39. [39] Item 7, MD&A — Consolidated Results
  40. [40] Item 7, MD&A — Consolidated Results
  41. [41] Item 7, MD&A — Consolidated Results
  42. [42] Item 7, MD&A — Consolidated Results
  43. [43] Item 7, MD&A — Consolidated Results
  44. [44] Item 7, MD&A — Operating Income
  45. [45] Item 7, MD&A — Revenue
  46. [46] Item 7, MD&A — Revenue
  47. [47] Item 7, MD&A — Revenue
  48. [48] Item 7, MD&A — Revenue
  49. [49] Item 7, MD&A — Revenue
  50. [50] Item 7, MD&A — Revenue
  51. [51] Item 7, MD&A — Revenue
  52. [52] Item 7, MD&A — Revenue
  53. [53] Item 7, MD&A — Revenue
  54. [54] Item 7, MD&A — Revenue
  55. [55] Item 7, MD&A — Revenue
  56. [56] Item 7, MD&A — Revenue
  57. [57] Item 7, MD&A — Revenue
  58. [58] Item 1, Business Segments
  59. [59] Item 1, Business Segments
  60. [60] Item 1, Business Segments
  61. [61] Item 1, Business Segments
  62. [62] Item 1, Business Segments
  63. [63] Item 1, Business Segments
  64. [64] Item 1, Business Segments
  65. [65] Item 7, MD&A — Goodwill Impairment Charge
  66. [66] Item 7, MD&A — Liquidity and Capital Resources
  67. [67] Item 7, MD&A — Liquidity and Capital Resources
  68. [68] Item 7, MD&A — Interest and Other Income (Expense), Net
  69. [69] Item 7, MD&A — Liquidity and Capital Resources
  70. [70] Item 7, MD&A — Operating Income
  71. [71] Item 7, MD&A — Operating Income
  72. [72] Item 1, Research and Development
  73. [73] Item 1, Research and Development
  74. [74] Item 1, Research and Development
  75. [75] Item 1, Research and Development
  76. [76] Item 7, MD&A — Income Tax Provision
  77. [77] Item 7, MD&A — Income Tax Provision
  78. [78] Item 7, MD&A — Income Tax Provision
  79. [79] Item 1A, Risk Factors — Risk Factor Summary
  80. [80] Item 1A, Risk Factors — New U.S. and reciprocal tariffs that have been imposed, and remain subject to potential change and other uncertainties, have had a material adverse effect on our business, results of operations and financial condition, and may continue to do so in the foreseeable future.
  81. [81] Item 1A, Risk Factors — A meaningful portion of our revenue is derived from U.S. academic institutions, research organizations and other entities that rely in part on U.S. academic and government funding, including NIH, NSF and DOE grants. The current reduction in the level of funding and delay in such research funding, has had a material adverse effect on our U.S. academic and governmental customers, and our business, results of operations and financial condition, and may continue to do so in the foreseeable future.
  82. [82] Item 1A, Risk Factors — We derive a significant portion of our revenue from international sales and are subject to the operational risks of doing business in foreign countries due to potential macroeconomic effects, including financial market volatility and disruption, inflationary concerns, changes in tax laws and regulations, volatility in interest and currency exchange rates, uncertain economic conditions in the United States and abroad, the impact of the recent U.S. government shutdown, and additional tariffs, including those imposed or that may be imposed by the current administration in the U.S.
  83. [83] Item 1A, Risk Factors — We derive a significant portion of our revenue from international sales and are subject to the operational risks of doing business in foreign countries due to potential macroeconomic effects, including financial market volatility and disruption, inflationary concerns, changes in tax laws and regulations, volatility in interest and currency exchange rates, uncertain economic conditions in the United States and abroad, the impact of the recent U.S. government shutdown, and additional tariffs, including those imposed or that may be imposed by the current administration in the U.S.
  84. [84] Item 1A, Risk Factors — Goodwill, intangible assets and other long-lived assets are subject to impairment which has had and could continue to negatively impact our operating results.
  85. [85] Item 1A, Risk Factors — Goodwill, intangible assets and other long-lived assets are subject to impairment which has had and could continue to negatively impact our operating results.
  86. [86] Item 1A, Risk Factors — Our products compete in markets that are subject to rapid technological change, and one or more of the technologies underlying our products could be made obsolete by new technology.
  87. [87] Item 1A, Risk Factors — We face substantial competition in our industries and expect that such competition will continue. If we fail to compete effectively, it could harm our business results and materially impact the value of our company.
  88. [88] Item 1A, Risk Factors — Disruptions at any of our manufacturing facilities could adversely affect our business.
  89. [89] Item 1A, Risk Factors — We rely on information technology to support our operations and reporting environments. A security failure of that technology, including with respect to cybersecurity risks and cyber incidents, could impact our ability to operate our businesses effectively, adversely affect our financial results, damage our reputation and expose us to potential liability or litigation.
  90. [90] Item 7, MD&A — Debt and Credit Facilities
  91. [91] Item 1A, Risk Factors — Our debt, which is principally denominated in foreign currency, is impacted by movement in foreign currency rates which may adversely affect our operations and cash flows and may restrict our investment opportunities or limit our activities.
  92. [92] Item 1A, Risk Factors — Changes in our effective income tax rate could adversely affect our results of operations.
  93. [93] Item 1A, Risk Factors — The ownership of our shares is highly concentrated, which could cause or exacerbate volatility in our share price as well as have significant influence over us.
  94. [94] Item 1A, Risk Factors — The ownership of our shares is highly concentrated, which could cause or exacerbate volatility in our share price as well as have significant influence over us.
  95. [95] Item 1A, Risk Factors — Our operations are dependent upon a limited number of suppliers and contract manufacturers.
  96. [96] Item 1, Research and Development
  97. [97] Item 1, Business Segments
  98. [98] Item 7, MD&A — Liquidity and Capital Resources
  99. [99] Item 7, MD&A — Liquidity and Capital Resources
  100. [100] Item 7, MD&A — Interest and Other Income (Expense), Net
  101. [101] Item 7, MD&A — Operating Income
  102. [102] Item 7, MD&A — Operating Income
  103. [103] Item 5, Market for Registrant’s Common Equity, Related Shareholder Matters and Issuer Purchases of Equity Securities
  104. [104] Item 7, MD&A — Non-GAAP Financial Measures (see “Non-GAAP Measures” below)
  105. [105] Item 7, MD&A — Non-GAAP Financial Measures (see “Non-GAAP Measures” below)
  106. [106] Item 7, MD&A — Non-GAAP Financial Measures (see “Non-GAAP Measures” below)
  107. [107] Item 7, MD&A — Non-GAAP Financial Measures (see “Non-GAAP Measures” below)
  108. [108] Item 7, MD&A — Non-GAAP Financial Measures (see “Non-GAAP Measures” below)
  109. [109] Item 7, MD&A — Non-GAAP Financial Measures (see “Non-GAAP Measures” below)
  110. [110] Item 7, MD&A — Non-GAAP Financial Measures (see “Non-GAAP Measures” below)
  111. [111] Item 7, MD&A — Non-GAAP Financial Measures (see “Non-GAAP Measures” below)
  112. [112] Item 7, MD&A — Non-GAAP Financial Measures (see “Non-GAAP Measures” below)
  113. [113] Item 7, MD&A — Non-GAAP Financial Measures (see “Non-GAAP Measures” below)
  114. [114] Item 1, Major Customers

Analysis on 5/20/2026